The Board has considered and accepted the resignation of Mrs. Dakshita Jain as Non Executive Independent Director of the Company w.e.f. November 24, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals Ltd has informed BSE that its Board accepted the resignation of Mrs. Dakshita Jain as Non-Executive Independent Director, effective November 24, 2025. The resignation was tendered due to personal and professional commitments, with no material reasons disclosed. The Board meeting where this was accepted ran from 5:00 PM to 5:30 PM on the same day. The company has filed the required Annexure-I disclosures under SEBI's Regulation 30 listing rules. The company is a small pharmaceutical entity listed on BSE (Scrip Code: 531015), headquartered in Hyderabad.
This is a single, routine independent director exit citing personal reasons with no governance red flags raised, so it is unlikely to materially affect the stock. Investors may, however, watch for timely appointment of a replacement independent director to maintain board composition compliance under SEBI norms.